Newer treatments for fibromyalgia syndrome

Therapeutics and Clinical Risk Management

Volumn 4, Issue 6, 2008, Pages 1331-1342

  Harris, Richard E ^a,b   Clauw, Daniel J ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

Author keywords

Fibromyalgia; Pain; Pharmacological; Treatment

Indexed keywords

AMITRIPTYLINE; CATECHOL METHYLTRANSFERASE; CITALOPRAM; DOPAMINE RECEPTOR; DULOXETINE; ENKEPHALIN; MILNACIPRAN; NEUROTRANSMITTER; PLACEBO; SEROTONIN 2A RECEPTOR; SEROTONIN TRANSPORTER; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT;

ANALGESIA; BEDTIME DOSAGE; BLOOD PRESSURE; CHRONIC PAIN; CLINICAL TRIAL; COGNITIVE THERAPY; CONSTIPATION; DISTRESS SYNDROME; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG MECHANISM; DRUG TOLERABILITY; ENVIRONMENTAL FACTOR; EXERCISE; FIBROMYALGIA; FLUSHING; FUNCTIONAL MAGNETIC RESONANCE IMAGING; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; HEART PALPITATION; HUMAN; NAUSEA; NEUROIMAGING; NOCICEPTION; PAIN ASSESSMENT; PAIN THRESHOLD; PATHOGENESIS; POSITRON EMISSION TOMOGRAPHY; POSTTRAUMATIC STRESS DISORDER; PROTEIN CEREBROSPINAL FLUID LEVEL; PSYCHOLOGICAL ASPECT; PULSE RATE; REVIEW; RISK FACTOR; SIDE EFFECT; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TREATMENT RESPONSE;

EID: 61549137546     PISSN: 11766336     EISSN: 1178203X     Source Type: Journal    
DOI: 10.2147/tcrm.s3396     Document Type: Review

References (115)

1. Aaron LA, Bradley LA, Alarcon GS, et al. 1996. Psychiatric diagnoses in patients with fibromyalgia are related to health care-seeking behavior rather than to illness. Arthritis Rheum, 39:436-45.
2. Aaron LA, Bradley LA, Alarcon GS, et al. 1997. Perceived physical and emotional trauma as precipitating events in fibromyalgia. Associations with health care seeking and disability status but not pain severity. Arthritis Rheum, 40:453-60.
3. Adelman LC, Adelman JU, Von Seggem R, et al. 2000. Venlafaxine extended release (XR) for the prophylaxis of migraine and tension-type headache: A retrospective study in a clinical setting. Headache, 40:572-80.
4. Adiguzel O, Kaptanoglu E, Turgut B, et al. 2004. The possible effect of clinical recovery on regional cerebral blood flow deficits in fibromyalgia: a prospective study with semiquantitative SPECT. South Med J, 97:651-55.
5. Alexander RW, Bradley LA, Alarcon GS, et al. 1998. Sexual and physical abuse in women with fibromyalgia: association with outpatient health care utilization and pain medication usage. Arthritis Care Res, 11: 102-15.
6. Anderberg UM, Marteinsdottir I, Von Knorring L. 2000. Citalopram in patients with fibromyalgia - a randomized, double-blind, placebo-controlled study. Ear J Pain, 4:27-35.
7. Arguelles LM, Afari N, Buchwald DS, et al. 2006. A twin study of posttraumatic stress disorder symptoms and chronic widespread pain. Pain, 124:150-7.
8. Arnold LM. 2007. Duloxetine and other antidepressants in the treatment of patients with fibromyalgia. Pain Med, 8:S63-S74.
9. Arnold LM, Hess EV, Hudson JI, et al. 2002. A randomized, placebo-controlled, double-blind, flexible-dose study of fluoxetine in the treatment of women with fibromyalgia. Am J Med, 112:191-7.
10. Arnold LM, Hudson JI, Hess EV, et al. 2004a. Family study of fibromyalgia. Arthritis Rheum, 50:944-52.
11. Arnold LM, Keck PEJ, Welge JA. 2000. Antidepressant treatment of fibromyalgia. A meta-analysis and review. Psychosomatics, 41:104-13.
12. Arnold LM, Lu Y, Crofford LJ, et al. 2004b. A double-blind, multicenter trial comparing duloxetine with placebo in the treatment of fibromyalgia patients with or without major depressive disorder. Arthritis Rheum, 50:2974-84.
13. Arnson Y, Amital D, Fostick L, et al. 2007. Physical activity protects male patients with post-traumatic stress disorder from developing severe fibromyalgia. Clin Exp Rheumatol, 25:529-33.
14. Baraniuk JN, Whalen G, Cunningham J, et al. 2004. Cerebrospinal fluid levels of opioid peptides in fibromyalgia and chronic low back pain. BMC Musculoskelet Disord, 5:48.
15. Barsky AJ, Borus JF. 1999. Functional somatic syndromes. Ann Intern Med, 130:910-21.
16. Bennett RM, Kamin M, Karim R, et al. 2003. Tramadol and acetaminophen combination tablets in the treatment of fibromyalgia pain: a double-blind, randomized, placebo-controlled study. Am J Med, 114:537-45.
17. Boisset-Pioro MH, Esdaile JM, Fitzeharles MA. 1995. Sexual and physical abuse in women with fibromyalgia syndrome. Arthritis Rheum, 38:235-41.
18. Bondy B, Spaeth M, Offenbaecher M, et al. 1999. The T102C polymorphism of the 5-HT2A-receptor gene in fibromyalgia. Neurobiol Dis, 6:433-9.
19. Briley M, Prost JF, Moret C. 1996. Preclinical pharmacology of milnacipran. Int Clin Psychopharmacol, 11:9-14.
20. Buskila D. 2007. Genetics of chronic pain states. Best Pract Res Clin Rheumatol, 21:535-47.
21. Buskila D, Cohen H, Neumann L, et al. 2004. An association between fibromyalgia and the dopamine D4 receptor exon III repeat polymorphism and relationship to novelty seeking personality traits. Mol Psychiatry, 9:730-1.
22. Buskila D, Neumann L, Hazanov I, et al. 1996. Familial aggregation in the fibromyalgia syndrome. Semin Arthritis Rheum, 26:605-11.
23. Buskila D, Neumann L, Vaisberg G, et al. 1997. Increased rates of fibromyalgia following cervical spine injury. A controlled study of 161 cases of traumatic injury. Arthritis Rheum, 40:446-52.
24. Buskila D, Sarzi-Puttini P, Ablin JN. 2007. The genetics of fibromyalgia syndrome. Pharmacogenomics, 8:67-74.
25. Capaci K, Hepguler S. 2002. Comparison of the effects of amitriptyline and paroxetine in the treatment of fibroinyalgia syndrome. The Pain Clinic, 14:223-8.
26. Chrousos GP, Gold PW 1992. The concepts of stress and stress system disorders. Overview of physical and behavioral homeostasis. JAMA, 267:1244-52.
27. Clauw DJ. 2003. The health consequences of the first Gulf war. Br Med J, 327:1357-8.
28. Clauw DJ. 2007. Fibromyalgia: update on mechanisms and management. J Clin Rheumatol, 13:102-9.
29. Clauw DJ, Chrousos GP. 1997. Chronic pain and fatigue syndromes: Overlapping clinical and neuroendocrine features and potential pathogenic mechanisms. Neuroimmunomodulation, 4:134-53.
30. Clauw DJ, Engel CC Jr, Aronowitz R, et al. 2003. Unexplained symptoms after terrorism and war: an expert consensus statement. J Occup Environ Med, 45:1040-8.
31. Clauw DJ, Katz P. 1995. The overlap between fibromyalgia and inflammatory rheumatic diseases: When and why does it occur? J Clin Rheum, 1:335-41.
32. Cook DB, Lange G, Ciccone DS, et al. 2004a. Functional imaging of pain in patients with primary fibromyalgia. J Rheumatol, 31:364-78.
33. Cöster L, Kendall S, Gerdle B, et al. 2007. Chronic widespread musculoskeletal pain - A comparison of those who meet criteria for fibromyalgia and those who do not. Eur J Pain, 12:600-10.
34. Croft P, Rigby AS, Boswell R, et al. 1993. The prevalence of chronic widespread pain in the general population. J Rheumatol, 20:710-3.
35. Derbyshire SW 2000. Exploring the pain "neuromatrix". Carr Rev Pain, 4:467-77.
36. Drossman DA. 1995. Sexual and physical abuse and gastrointestinal illness. Scand J Gastroenterol Suppl, 208; 90-96.
37. Drossman DA, Li ZM, Andruzzi E, et al. 1993. US householder survey of functional gastrointestinal disorders. Prevalence, sociodemography, and health impact. Dig Dis Sci, 38:1569-80.
38. Farber L, Stratz T, Bruckle W, et al. 2000. Efficacy and tolerability of tropisetron in primary fibromyalgia - A highly selective and competitive 5-HT3 receptor antagonist. German Fibromyalgia Study Group. Scand J Rheum Suppl, 113:49-54.
39. Fishbain D. 2000. Evidence-based data on pain relief with antidepressants. Ann Med, 32:305-16.
40. Fukuda K, Dobbins JG, Wilson LJ, et al. 1997. An epidemiologic study of fatigue with relevance for the chronic fatigue syndrome. J Psychiatr Res, 31:19-29.
41. Fukuda K, Nisenbaurn R, Stewart G, et al. 1998. Chronic multisymptom illness affecting Air Force veterans of the Gulf War. JAMA, 280:981-8.
42. Geisser ME, Gracely RH, Giesecke T, et al. 2007. The association between experimental and clinical pain measures among persons with fibromyalgia and chronic fatigue syndrome. Eur J Pain, 11:202-7.
43. Gendreau RM, Thorn MD, Gendreau JF, et al. 2005. The efficacy of milnacipran in fibromyalgia. J Rheumatol, 32:1975-85.
44. Giesecke J, Reed BD, Haefner HY, et al. 2004a. Quantitative sensory testing in vulvodynia patients and increased peripheral pressure pain sensitivity. Obstet Gynecol, 104:126-33.
45. Giesecke T, Gracely RH, Williams DA, et al. 2005. The relationship between depression, clinical pain, and experimental pain in a chronic pain cohort. Arthritis Rheum, 52:1577-84.
46. Giesecke T, Gracely RH, Grant MA, et al. 2004b. Evidence of augmented central pain processing in idiopathic chronic low back pain. Arthritis Rheum, 50:613-23.
47. Glass JM, Lyden A, Petzke F, et al. 2004. The effect of brief exercise cessation on pain, fatigue, and mood symptom development in healthy, fit individuals. J Psychosom Res, 57:391-8.
48. Goldenberg D, Mayskiy M, Mossey C, et al. 1996. A randomized, double-blind crossover trial of fluoxetine and amitriptyline in the treatment of fibromyalgia. Arthritis Rheum, 39:1852-9.
49. Goldenberg DL, Burckhardt C, Crofford L. 2004. Management of fibromy-algia syndrome. JAMA, 292:2388-95.
50. Gowans SE, de Hueck A, Voss S, et al. 2001. Effect of a randomized, controlled trial of exercise on mood and physical function in individuals with fibromyalgia. Arthritis Rheum, 45:519-29.
51. Gracely RH, Geisser ME, Giesecke T, et al. 2004. Pain catastrophizing and neural responses to pain among persons with fibromyalgia. Brain, 127(Pt 4):835-43.
52. Gracely RH, Grant MA, Giesecke T. 2003. Evoked pain measures in fibromyalgia. Best Pract Res Clin Rheumatol, 17:593-609.
53. Gracely RH, Petzke F, Wolf JM, et al. 2002. Functional magnetic resonance imaging evidence of augmented pain processing in fibromyalgia. Arthritis Rheum, 46:1333-43.
54. Granges G, Littlejohn G. 1993. Pressure pain threshold in pain-free subjects, in patients with chronic regional pain syndromes, and in patients with fibromyalgia syndrome, Arthritis Rheum, 36:642-6.
55. Guedj E, Cammilleri S, Colavolpe C, et al. 2007a. Predictive value of brain perfusion SPECT for ketamine response in hyperalgesic fibromyalgia. Ear J Nucl Med Mol Imaging, 34:1274-9.
56. Guedj E, Taieb D, Cammilleri S, et al. 2007b. 99mTc-ECD brain perfusion SPECT in hyperalgesic fibromyalgia. Eur J Nucl Med Mol Imaging, 34:130-4.
57. Harris RE, Clauw DJ, Scott DJ, et al. 2007. Decreased central mu-opioid receptor availability in fibromyalgia. J Neurosci, 27:10000-6.
58. Harris RE, Gracely RH, McLean SA, et al. 2006. Comparison of clinical and evoked pain measures in fibromyalgia. J Pain, 7:521-7.
59. Harris RE, Sundgren PC, Pang Y, et al. 2008. Dynamic levels of glutamate within the insula are associated with improvements in multiple pain domains in fibromyalgia. Arthritis Rheum, 58:903-7.
60. Heim C, Newport DJ, Bonsall R, et al. 2001. Altered pituitary-adrenal axis responses to provocative challenge tests in adult survivors of childhood abuse. Am J Psychiatry, 158:575-81.
61. Hudson JI, Goldenberg DL, Pope HGJ, et al. 1993. Comorbidity of fibromyalgia with medical and psychiatric disorders. Am J Med, 92:363-7.
62. Hudson JI, Hudson MS, Pliner LF, et al. 1985. Fibromyalgia and major affective disorder: A controlled phenomenology and family history study. Am J Psychiatry, 142:441-6.
63. Hyams KC, Wignall FS, Roswell R. 1996. War syndromes and their evaluation: from the US Civil War to the Persian Gulf War. Ann Intern Med, 125:398-405.
64. Jacobsen S, Bredkjaer SR. 1992. The prevalence of fibromyalgia and widespread chronic musculoskeletal pain in the general population. Scand J Rheumatol, 21:261-3.
65. Jacobsen S, Danneskiold-Samsoe B, Andersen RB. 1991. Oral S-adenosylmethionine in primary fibromyalgia. Double-blind clinical evaluation. Scand J Rheumatol, 20:294-302.
66. Jensen K, Andersen HO, Olesen J, et al. 1986. Pressure-pain threshold in human temporal region. Evaluation of a new pressure algometer. Pain, 25:313-23.
67. Julien N, Goffaux P, Arsenault P, et al. 2005. Widespread pain in fibromyalgia is related to a deficit of endogenous pain inhibition. Pain, 114:295-302.
68. Kato K, Sullivan PF, Evengard B, et al. 2006b. Chronic widespread pain and its comorbidities: a population-based study. Arch Intern Med, 166:1649-54.
69. Kato K, Sullivan PF, Evengard B, et al. 2006a. Importance of genetic influences on chronic widespread pain. Arthritis Rheum, 54:1682-6.
70. Khan AA, Khan A, Harezlak J, et al. 2003. Somatic symptoms in primary care: etiology and outcome. Psychosomatics, 44:471-8.
71. Kop WJ, Lyden A, Berlin AA, et al. 2005. Ambulatory monitoring of physical activity and symptoms in fibromyalgia and chronic fatigue syndrome. Arthritis Rheum, 52:296-303.
72. Kosek E, Hansson P. 1997. Modulatory influence on somatosensory perception from vibration and heterotopic noxious conditioning stimulation (HNCS) in fibromyalgia patients and healthy subjects. Pain, 70:41-51.
73. Kwiatek R, Barnden L, Tedman R, et al. 2000. Regional cerebral blood flow in fibromyalgia: single-photon-emission computed tomography evidence of reduction in the pontine tegmentum and thalami. Arthritis Rheum, 43:2823-33.
74. Lautenbacher S, Rollman GB. 1997. Possible deficiencies of pain modulation in fibromyalgia. Clin J Pain, 13:189-96.
75. Leffler AS, Hansson P, Kosek E. 2002. Somatosensory perception in a remote pain-free area and function of diffuse noxious inhibitory controls (DNIC) in patients suffering from long-term trapezius myalgia. Eur J Pain, 6:149-59.
76. Maixner W, Fillingim R, Booker D, et al. 1995. Sensitivity of patients with painful temporomandibular disorders to experimentally evoked pain. Pain, 63:341-51.
77. Mayer EA, Raybould HE. 1990. Role of visceral afferent mechanisms in functional bowel disorders. Gastroenterology, 99:1688-704.
78. McBeth J, Silman AJ, Gupta A, et al. 2007. Moderation of psychosocial risk factors through dysfunction of the hypothalanlic-pituitary-adrenal stress axis in the onset of chronic widespread musculoskeletal pain: findings of a population-based prospective cohort study. Arthritis Rheum, 56:360-71.
79. McLean SA, Clauw DJ. 2004. Predicting chronic symptoms after an acute "stressor" - lessons learned from 3 medical conditions. Med Hypotheses, 63:653-8.
80. Moldofsky H, Scarisbrick P, England R, et al. 1975. Musculosketal symptoms and non-REM sleep disturbance in patients with "fibrositis syndrome" and healthy subjects. Psychosom Med, 37:341-51.
81. Moshiree B, Price DD, Robinson ME, et al. 2007. Thermal and visceral hypersensitivity in irritable bowel syndrome patients with and without fibromyalgia. Clin J Pain, 23:323-30.
82. Mountz JM, Bradley LA, Modell JG, et al. 1995. Fibromyalgia in women. Abnormalities of regional cerebral blood flow in the thalamus and the caudate nucleus are associated with low pain threshold levels. Arthritis Rheum, 38:926-38.
83. Naliboff BD, Derbyshire SW, Munakata J, et al. 2001. Cerebral activation in patients with irritable bowel syndrome and control subjects during rectosigmoid stimulation. Psychosom Med, 63:365-75.
84. Norregaard J, Volkmann H, Danneskiold-Samso, B. 1995. A randomized controlled trial of citalopram in the treatment of fibromyalgia. Pain, 61:445-9.
85. O'Malley PG, Balden E, Tomkins G, et al. 2000. Treatment of fibromyalgia with antidepressants. A meta-analysis. J Gen Intern Med, 15:659-66.
86. Offenbaecher M, Bondy B, de Jonge S, et al. 1999. Possible association of fibromyalgia with a polymorphism in the serotonin transporter gene regulatory region. Arthritis Rheum, 42:2482-8.
87. Peleg R, Ablin JN, Peleg A, et al. 2007. Characteristics of fibromyalgia in Muslim Bedouin women in a primary care clinic. Semin Arthritis Rheum, 37:398-402.
88. Petzke F, Clauw DJ, Ambrose K, et al. 2003a. Increased pain sensitivity in fibromyalgia: effects of stimulus type and mode of presentation. Pain, 105:403-13.
89. Petzke F, Gracely RH, Khine A, et al. 1999. Pain sensitivity in patients with fibromyalgia (fibromyalgia): Expectancy effects on pain measurements. Arthritis Rheum, 42:S342.
90. Petzke F, Gracely RH, Park KM, et al. 2003b. What do tender points measure? Influence of distress on 4 measures of tenderness. J Rheumatol, 30:567-74.
91. Petzke F, Khine A, Williams D, et al. 2001. Dolorimetry performed at 3 paired tender points highly predicts overall tenderness. J Rheumatol, 28:2568-9.
92. Pillow DR, Zautra Al, Sandler I. 1996. Major life events and minor stressor: identifying mediational links in the stress process. J Pers Soc Psychol, 70:381-94.
93. Raphael KG, Natelson BH, Janal MN, et al. 2002. A community-based survey of fibromyalgia-tike pain complaints following the World Trade Center terrorist attacks. Pain, 100: 131-9.
94. Raspe H. 1992. [Rheumatism epidemiology in Europe]. Soz Praventivmed, 37:169-79.
95. Russell IJ, Vaeroy H, Javors M, et al. 1992. Cerebrospinal fluid biogenic amine metabolites in fibromyalgia/fibrositis syndrome and rheumatoid arthritis. Arthritis Rheum, 35:550-6.
96. Sapolsky RM. 1996. Why stress is bad for your brain. Science, 273:749-50.
97. Sarchielli P, Di Filippo M, Nardi K, et al. 2007. Sensitization, glutamate, and the link between migraine and fibromyalgia, Curr Pain Headache Rep, 11:343-51.
98. Scudds RA, McCain GA, Rollman GB, et al. 1989. Improvements in pain responsiveness in patients with fibrositis after successful treatment with amitriptyline. J Rheumatol Suppl, 19:98-103.
99. Smythe HA, Moldofsky H. 1977. Two contributions to understanding of the "fibrositis" syndrome. Bull Rheum Dis, 28:928-31.
100. Unwin C, Blatchley N, Coker W, et al. 1999. Health of UK servicemen who served in Persian Gulf War. Lancet, 353:169-79.
101. Vitton O, Gendreau M, Gendreau J, et al. 2004. A double-blind placebo-controlled trial of milnacipran in the treatment of fibromyalgia. Hum Psychopharmacol, 19:S27-S35.
102. Wessely S, Ninmuan C, Sharpe M. 1999. Functional somatic syndromes: One or many? Lancet, 354:936-9.
103. White KP, Thompson J. 2003. Fibromyalgia syndrome in an Amish community: a controlled study to determine disease and symptom prevalence. J Rheumatol, 30:1835-40.
104. Wilder-Smith CH, Robert-Yap J. 2007. Abnormal endogenous pain modulation and somatic and visceral hypersensitivity in female patients with irritable bowel syndrome. World J Gastroenterol, 13:3699-704.
105. Williams DA, Brown SC, Clauw DJ, et al. 2003. Self-reported symptoms before and after September 11 in patients with fibromyalgia. JAMA, 289:1637-8.
106. Wolfe F. 1997. The relation between tender points and fibromyalgia symptom variables: evidence that fibromyalgia is not a discrete disorder in the clinic. Ann Rheum Dis, 56:268-71.
107. Wolfe F, Ross K, Anderson J, et al. 1995. Aspects of fibromyalgia in the general population: Sex, pain threshold, and fibromyalgia symptoms. J Rheumatol, 22:151-6.
108. Wolfe F, Smythe HA, Yunus MB, et al. 1990. The American College of Rheumatology 1990 Criteria for the Classification of Fibromyalgia. Report of the Multicenter Criteria Committee. Arthritis Rheum, 33:160-72.
109. Woolf CJ. 2004. Pain: moving from symptom control toward mechanism-specific pharmacologic management. Ann Intern Med, 140:441-51.
110. Yunus M, Masi AT, Calabro JJ, et al. 1991. Primary fibromyalgia (fibrositis): Clinical study of 50 patients with matched normal controls. Semin Arthritis Rheum, 11: 151-71.
111. Yunus MB. 2008. Central sensitivity syndromes: a new paradigm and group nosology for fibromyalgia and overlapping conditions, and the related issue of disease versus illness. Semin Arthritis Rheum, 37:339-52.
112. Yunus MB. 1992. Towards a model of pathophysiology of fibromyalgia: Aberrant central pain mechanisms with peripheral modulation. J Rheumatol, 19:846-50.
113. Yunus MB, Dailey JW, Aldag JC, et al. 1992. Plasma tryptophan and other amino acids in primary fibromyalgia: A controlled study. J Rheumatol, 19:90-4.
114. Yunus MB, Young CS, Saeed AS, et al. 2004. Positron emission tomography imaging of the brain in fibromyalgia syndrome. Arthritis Rheum, 51:513-8.
115. Yunus MB, Young CS, Saeed AS, et al. 1997. Positron emission tomography (PET) imaging of the brain in fibromyalgia syndrome (fibromyalgias). Arthritis Rheum, 40:S188.